Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.0852W HIGH $20,123.75
Volume
4.90 M
Value Traded
132.85 K
Short % Float
25.39%
Days to Cover
1.0
-49.69%Week
-95.79%1 Month
-99.89%3 Month
-99.99%6 Month
-100%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
61.66 K
EPS (TTM)
-48.20
P/E Ratio
-
Ent. Value
-685.34 K
Total Shares
770.73 K
Float Shares
510.00 K
Insiders
54.87%
Institutions
0.06%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CDT Catalyst Timeline
Dated clinical, regulatory and corporate events for CDT Equity Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for CDT Equity Inc.
34Total events
1Upcoming
9Tier-1 (high impact)
2022 to 2026Coverage
Upcoming catalysts 1
TBD
T2Trial Initiation
Subscribe to view catalyst details
Event history 27
●Reverse Stock SplitCorporate
Common stock expected to begin trading on reverse split-adjusted basis on Nasdaq
▲Patent GrantedAZD5904IP / Competition
Canadian patent granted for AZD5904 in male infertility
male infertilitysource ↗
▲Composition Patent FiledtapinarofIP / Competition
Filed two new patent applications for tapinarof combination therapy and cocrystal forms
psoriasis, atopic dermatitissource ↗
▲Composition Patent FiledIP / Competition
Sarborg filed U.S. provisional patent application for AI Signature Agent
▲Preclinical PoCAZD1656Preclinical
Positive pre-clinical data validating new biological target for AZD1656
▲Partnership / LicenseCorporate
Conduit enters joint development agreement with Manoira for AZD1656 and AZD5658 in animal health
▼Reverse Stock SplitCorporate
1-for-15 reverse stock split approved by board, effective May 19, 2025
▼Reverse Stock SplitCorporate
1-for-100 reverse stock split approved by board, effective January 24, 2025
▲Partnership / LicenseCorporate
Partnership with SARBORG Limited to leverage AI and cybernetics platform
▲Partnership / LicenseCorporate
Conduit enters exclusive license agreement with AstraZeneca for AZD1656, AZD5658, and AZD5904
◆Trial InitiationAZD1656Trial
Conduit intends to initiate Phase II trials for AZD1656 in autoimmune disorders in 2024
autoimmune disorderssource ↗
◆Trial InitiationAZD5658Trial
Conduit intends to initiate Phase II trials for AZD5658 in autoimmune disorders in 2024
autoimmune disorderssource ↗
◆AcquisitionCorporate
Postponement of special meeting of stockholders to approve business combination with Conduit Pharmaceuticals
◆Quarterly UpdateCorporate
Special meeting of stockholders postponed from September 7 to September 13, 2023
◆Quarterly UpdateCorporate
Special Meeting of MURF Stockholders to vote on business combination and related proposals
▲FDA Filing AcceptedRegulatory Filing
SEC declares Form S-4 registration statement effective for business combination
Past FDA Catalysts and PDUFA Decisions
How CDT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every CDT program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Regan AndrewDirector, Officer (Chief Executive Officer) | Sell | -290 5,692,933 held | $0.00 | 08/28/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CDT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in CDT for Q2 2026. | ||||
CDT Institutional Ownership Trends
CDT Short Interest
Shares sold short, counted twice a month.
25.39%
Short % of Float
of tradable shares sold short
129.5K
Shares Sold Short
+239.0% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
2.5M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CDT ranks across every disease it competes in
Competitive Position is a premium feature
See how CDT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCDT News
-CDT
Oct 27, 2026▼ -8.6%today
CDT Partners with Manoira to Explore Enhancing Animal Health Products Ahead of Launch
CDT Equity Inc. has partnered with Manoira Corporation to evaluate its clinical-stage assets, AZD1656 and AZD5904, for enhancing Manoira's upcoming animal health products. Manoira plans to launch its first product range in early 2027, focusing on cannabinoid cocrystal technologies. Successful evaluation may lead to licensing discussions for commercialization.
Read more →-CDT
Oct 14, 2026▼ -46.7%on this news· ran to -59% by day 3
CDT Highlights Sarborg's Solid-Form Patent Filing on a First-in-Class Respiratory Asset
CDT Equity Inc. announced Sarborg Limited's patent filing for novel solid forms of a first-in-class respiratory medicine. This filing enhances Sarborg's intellectual property portfolio and opens up new opportunities in a market valued over $20 billion annually. CDT holds a significant stake in Sarborg, valued at around $161 million.
Read more →-CDT
Sep 29, 2026▼ -23.7%on this news· ran to -48% by day 3
CDT Highlights Sarborg’s Expanding Quantum Computing IP Portfolio and Application to Drug Discovery
CDT Equity Inc. announced Sarborg Limited's new intellectual property focused on applying quantum sampling to drug discovery. This innovative approach targets disease biology across 150 networks, including conditions like Crohn's disease and COPD. Sarborg's model shows promise in identifying druggable targets and has garnered interest from a major quantum computing firm.
Read more →-CDT
Sep 25, 2026▼ -33.9%on this news· ran to -55% by day 3
CDT Equity Inc. Announces Reverse Stock Split
CDT Equity Inc. has announced a 1-for-25 reverse stock split approved by its board of directors to comply with Nasdaq's bid-price rule. The split will take effect on September 28, 2026, with trading on a reverse-adjusted basis starting September 29, 2026. This move aims to enhance the stock's marketability while maintaining the current par value of shares.
Read more →-CDT
Sep 18, 2026▼ -8.2%on this news· ran to -29% by day 3
CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo
CDT Equity Inc. has partnered with QIMA Life Sciences to evaluate new combinations of tapinarof for psoriasis and vitiligo. This collaboration aims to leverage patient-derived skin samples to enhance the efficacy of treatments. Tapinarof is already a leading treatment for plaque psoriasis and atopic dermatitis, and the partnership seeks to address significant unmet needs in autoimmune skin diseases.
Read more →-CDT
Sep 10, 2026▼ -42.5%on this news· ran to -66% by day 3
CDT Highlights Sarborg’s Application of Signature Intelligence and Quantum Computing Models to Mental Health
CDT Equity Inc. announced Sarborg Limited's successful use of its Signature Intelligence and quantum computing models for mental health drug discovery. This technology aims to identify relationships between neuropsychiatric disease signatures and therapeutic candidates. Sarborg is engaging with various organizations for potential collaborations in this area.
Read more →-CDT
Sep 2, 2026CDT Provides Capital Update and Confirms No Nasdaq Deficiencies
CDT Equity Inc. announced a capital update, reporting 13,693,866 shares outstanding and a market capitalization of about $23.0 million as of August 31, 2026. The company confirmed it has no deficiencies with Nasdaq following recent share issuances. Stockholders' equity stands at approximately $103 million, reflecting a stable financial position.
Read more →-CDT
Sep 1, 2026▼ -11.9%on this news· ran to -63% by day 3
CDT Appoints Co-Founder James Bligh as Chief Executive Officer to Lead Next Phase of Growth
CDT Equity Inc. appointed co-founder James Bligh as CEO to guide the company’s growth. Bligh, who has extensive experience in public markets and corporate finance, aims to enhance shareholder value. The company has recently strengthened its balance sheet and made strategic investments, including a stake in Sarborg. CDT is focused on identifying and advancing high-potential therapeutic assets.
Read more →-CDT
Aug 28, 2026▼ -10.1%on this news· ran to -52% by day 3shared move
CDT Validates Enhanced Solid-Form Properties Within Its IP Portfolio
CDT Equity Inc. announced the validation of new solid forms of its drug compounds, which exhibit improved stability and solubility. These enhancements are protected under patent law and aim to support new formulations for underserved patient groups. The company plans to advance these findings into clinical models to further explore their therapeutic potential.
Read more →-CDT
Aug 25, 2026▼ -17.7%on this news· ran to -32% by day 3shared move
CDT Announces Investment in Pep'd, Expanding into the Fast-Growing US Peptide Market
CDT Equity Inc. announced an investment in Pep'd Inc., enhancing its presence in the US peptide market. This strategic move aims to leverage AI in peptide development and capitalize on the growing demand for peptide therapeutics. Pep'd has already launched its platform and is generating revenue, indicating early commercial success.
Read more →-CDT
Aug 3, 2026CDT Increases Stake in Sarborg following its Quantum Computing and Intellectual Property Expansion
CDT Equity Inc. announced an increase in its stake in Sarborg Limited to 22.7% through pre-funded warrants, pending shareholder approval. This move reflects Sarborg's progress in expanding its Signature Intelligence platform into quantum computing and agriculture. The company has also built a robust intellectual property portfolio, enhancing its market reach.
Read more →-CDT
Jul 20, 2026▲ +13.8%on this news
CDT Highlights Sarborg's Patent Filing Extending Quantum-Enabled PRISM Platform to Sugarcane
CDT Equity Inc. highlighted Sarborg Limited's new patent application for sugarcane cultivation interventions. The filing covers 606 field-deployable combinations identified via the quantum-enabled PRISM platform. This expansion moves SarborgQ beyond pharmaceuticals into agriculture. CDT holds a 20% stake in Sarborg, reinforcing its strategic investment.
Read more →-CDT
Jun 26, 2026▼ -10.8%on this news· ran to -27% by day 3
CDT Highlights Sarborg's Application of Quantum Computing to Solid-Form Development
CDT Equity Inc. announced Sarborg Limited's expansion of its Signature Intelligence platform into quantum-assisted coformer selection. This initiative aims to enhance solid-form development and improve decision-making using quantum computing. The company plans to deploy these capabilities across its intellectual property portfolio and offer them to external partners. CDT views this as a significant step in Sarborg's development.
Read more →-CDT
Jun 18, 2026▲ +47.2%on this news· ran to +116% by day 1
CDT Notes Strategic Investment into Sarborg and Expansion into Quantum Computing
CDT Equity Inc. announced its strategic investment in Sarborg Limited, which raised funds for its new quantum computing division, SarborgQ. This investment, valued at $127.5 million for CDT, aims to enhance Sarborg's Signature Intelligence platform. The initiative is expected to improve analysis of complex biological systems and expand capabilities beyond classical computing.
Read more →-CDT
Jun 16, 2026CDT Equity Announces Debt Update and New Loan Facility
CDT Equity Inc. has successfully restructured its debt, eliminating over $6.3 million in legacy obligations. The company repaid its previous loans and entered a new loan agreement with JJ Astor for up to $1,460,000 to support its working capital. This restructuring is expected to enhance CDT's financial flexibility and allow it to focus on its strategic goals.
Read more →-CDT
May 28, 2026▼ -13.6%on this news
CDT Equity Inc. Announces Receipt of Nasdaq Deficiency Letter
CDT Equity Inc. announced it received a deficiency notice from Nasdaq for not filing its Quarterly Report on Form 10-Q on time. The notice does not impact the current trading of CDT's securities immediately. The company has until July 20, 2026, to submit a compliance plan. CDT aims to file the report as soon as possible to regain compliance.
Read more →-CDT
May 27, 2026▲ +24.4%on this newsshared move
CDT Announces Canadian Patent for AZD5904 in Male Infertility
CDT Equity Inc. has announced the granting of a patent for AZD5904 in Canada, completing its approval in key pharmaceutical markets. This patent enhances CDT's intellectual property position as they explore licensing and partnership opportunities. AZD5904 is positioned to address a significant unmet need in the male infertility market, which is valued at approximately $4.4 billion annually.
Read more →-CDT
May 7, 2026CDT Notes Sarborg Filing of Substance of Matter Patent in Cystic Fibrosis Market
CDT Equity Inc. noted Sarborg Limited's filing of a new Substance of Matter patent for two established cystic fibrosis compounds. This patent was developed using Sarborg's proprietary platform, allowing rapid identification of therapeutic opportunities. CDT, a 20% shareholder in Sarborg, views this as a significant validation of their capabilities and plans to evaluate potential combination therapies.
Read more →-CDT
May 6, 2026CDT Advances AZD5904 into Global Patent Phase and Initiates Partnering Discussions
CDT Equity Inc. announced that AZD5904 has entered the Patent Cooperation Treaty phase, enhancing its global IP protection. The drug, which has shown a favorable safety profile in clinical trials, is being positioned for downstream development and partnerships. CDT aims to leverage its strong clinical data and patent protections to attract pharmaceutical partners.
Read more →About CDT Equity Inc.
Headquarters4851 TAMIAMI TRAIL NORTH, NAPLES, FL, 34103
BIOPHARMAWATCH ELITE PLUS
Trade the next CDT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime